Prospective Grant of Exclusive License: (N)-Methanocarba Adenosine Derivative as A3 Receptor Agonists, 38890-38891 [E6-10727]
Download as PDF
<![CDATA[
38890
Federal Register / Vol. 71, No. 131 / Monday, July 10, 2006 / Notices
review by the TRR Subcommittee and
NTP staff prior to the meeting. Persons
needing special assistance, such as sign
language interpretation or other
reasonable accommodation in order to
attend, should contact 919–541–2475
(voice), 919–541–4644 TTY (text
telephone), through the Federal TTY
Relay System at 800–877–8339, or by email to niehsoeeo@niehs.nih.gov.
Requests should be made at least 7 days
in advance of the event.
ADDRESSES: The TRR Subcommittee
meeting will be held in the Rodbell
Auditorium, Rall Building at the NIEHS,
111 T. W. Alexander Drive, Research
Triangle Park, NC 27709. A copy of the
preliminary agenda, committee roster,
and any additional information, when
available, will be posted on the NTP
Web site (https://ntp.niehs.nih.gov/
select ‘‘Calendar of Upcoming Events’’)
or provided upon request. Public
comments and any other
correspondence should be submitted to
Dr. Barbara Shane, Executive Secretary
for the NTP Board (NTP Liaison and
Scientific Review Office, NIEHS, P.O.
Box 12233, MD A3–01, Research
Triangle Park, NC 27709; telephone:
919–541–4253, fax: 919–541–0295; or email: shane@niehs.nih.gov).
SUPPLEMENTARY INFORMATION:
Background
The primary agenda topic is the peer
review of the findings and conclusions
of five draft NTP Technical Reports of
rodent toxicology and carcinogenicity
studies conducted by the NTP (see
Preliminary Agenda below) in
genetically modified mouse models. The
TRR Subcommittee will also provide
advice to the NTP on the utility of GMM
models for cancer hazard identification.
sroberts on PROD1PC70 with NOTICES
Attendance and Registration
The meeting is scheduled for August
28, 2006, from 8:30 a.m. to adjournment
and is open to the public with
attendance limited only by the space
available. Individuals who plan to
attend are encouraged to register online
at the NTP website by August 14, 2006,
at https://ntp.niehs.nih.gov/ select
‘‘Advisory Boards and Committees’’ to
facilitate access to the NIEHS campus.
Please note that a photo ID is required
to access the NIEHS campus. The NTP
is making plans to videocast the meeting
through the Internet at https://
www.niehs.nih.gov/external/video.htm.
Availability of Meeting Materials
A copy of the preliminary agenda,
committee roster, and any additional
information, when available, will be
posted on the NTP Web site (https://
ntp.niehs.nih.gov/ select ‘‘Calendar of
VerDate Aug<31>2005
17:10 Jul 07, 2006
Jkt 208001
Upcoming Events’’) or may be requested
in hardcopy from the Executive
Secretary (see ’’ADDRESSES above).
Following the meeting, summary
minutes will be prepared and made
available on the NTP Web site.
reproductive toxicology or teratology,
and biostatistics. Its members are
invited to serve overlapping terms of up
to four years. BSC and TRR
Subcommittee meetings are held
annually or biannually.
Request for Comments
Public input at this meeting is invited
and time is set aside for the presentation
of public comments on any draft
technical report. Each organization is
allowed one time slot per agenda topic.
At least 7 minutes will be allotted to
each speaker, and if time permits, may
be extended to 10 minutes. Registration
for oral comments will also be available
on-site, although time allowed for
presentation by on-site registrants may
be less than that for pre-registered
speakers and will be determined by the
number of persons who register at the
meeting.
Persons registering to make oral
comments are asked, if possible, to send
a copy of their statement to Dr. Shane
(see ADDRESSES above) by August 14,
2006, to enable review by the TRR
Subcommittee and NTP staff prior to the
meeting. Written statements can
supplement and may expand the oral
presentation. If registering on-site and
reading from written text, please bring
40 copies of the statement for
distribution to the TRR Subcommittee
and NTP staff and to supplement the
record. Written comments received in
response to this notice will be posted on
the NTP Web site. Persons submitting
written comments should include their
name, affiliation, mailing address,
phone, fax, e-mail, and sponsoring
organization (if any) with the document.
Dated: June 27, 2006.
Samuel H. Wilson,
Deputy Director, National Institute of
Environmental Health Sciences and the
National Toxicology Program.
Background Information on the NTP
Board of Scientific Counselors
The NTP Board of Scientific
Counselors (BSC) is a technical advisory
body comprised of scientists from the
public and private sectors who provide
primary scientific oversight to the
overall program and its centers.
Specifically, the BSC advises the NTP
on matters of scientific program content,
both present and future, and conducts
periodic review of the program for the
purposes of determining and advising
on the scientific merit of its activities
and their overall scientific quality. The
TRR Subcommittee is a standing
subcommittee of the BSC. BSC members
are selected from recognized authorities
knowledgeable in fields such as
toxicology, pharmacology, pathology,
biochemistry, epidemiology, risk
assessment, carcinogenesis,
mutagenesis, molecular biology,
behavioral toxicology and
neurotoxicology, immunotoxicology,
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Preliminary Agenda; National
Toxicology Program (NTP) Board of
Scientific Counselors Technical Reports
Review Subcommittee Meeting; August
28, 2006; Rodbell Auditorium, Rall
Building, National Institute of
Environmental Health Sciences, 111
TW Alexander Drive, Research
Triangle Park, NC
NTP Technical Reports (TR) Scheduled
for Review
• GMM 07: Allyl Bromide (CASNR
106–95–6).
Æ Chemical intermediate in the
manufacture of polymers,
pharmaceuticals, and agricultural
products.
• GMM 09:
Dicyclohexylcarbodiimide (CASNR
538–75–0).
Æ Reagent in the chemical and
pharmaceutical industries; stabilizing
agent in elastomers, synthetic rubber,
and other types of resins.
• GMM 08: Benzene (CASNR 71–43–
2).
Æ Used in the manufacture of
medicinal chemicals, dyes, oil,
varnishes, and lacquers.
• GMM 13: Glycidol (CASNR 556–
52–5).
Æ Stabilizer in the manufacture of
vinyl polymers; additive for oil and
synthetic hydraulic fluids.
• GMM 12: Phenolphthalein (CASNR
77–09–8).
Æ Laboratory reagent; cathartic drug
in laxatives.
• The utility of genetically modified
models for cancer hazard identification.
[FR Doc. E6–10728 Filed 7–7–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: (N)-Methanocarba Adenosine
Derivative as A3 Receptor Agonists
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
E:\FR\FM\10JYN1.SGM
10JYN1
sroberts on PROD1PC70 with NOTICES
Federal Register / Vol. 71, No. 131 / Monday, July 10, 2006 / Notices
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
license worldwide to practice the
invention embodied in: International
Patent Application PCT/US2005/031678
filed September 2, 2005 entitled, ‘‘(N)Methanocarba Adenosine Derivative as
A3 Receptor Agonists’’, to Can-Fite
BioPharma, Ltd. having a place of
business in Petach-Tikva, Israel. The
contemplated exclusive license may be
limited to an FDA approvable human
therapeutic for cancer, autoimmune and
other inflammatory diseases. The
United States of America is the assignee
of the patent rights in this invention.
DATES: Only written comments and/or
application for a license which is
received by the NIH Office of
Technology Transfer on or before
September 8, 2006 will be considered.
ADDRESSES: Request for a copy of the
patent, inquiries, comments, and other
materials relating to the contemplated
license should be directed to: Norbert
Pontzer, Technology Licensing
Specialist, Office of Technology
Transfer, National Institutes of Health,
6011 Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
301–435–5502; Facsimile: 301–402–
0220; e-mail: pontzern@mail.nih.gov.
SUPPLEMENTARY INFORMATION:
Researchers have been pursuing
compounds that activate or inhibit
adenosine A3 receptors because these
cell membrane proteins have a wide
range of physiological and diseaserelated effects and are thus considered
to be promising drug targets. The
adenosine A3 receptors are G-proteincoupled receptors and are found mostly
in brain, lung, liver, heart, kidney, and
testis. When this receptor is activated
moderately, a cytoprotective effect is
observed, such as reducing damage to
heart cells from lack of oxygen.
However, at high levels of stimulation
they can cause cell death. Both agonists
and antagonists are being tested for
therapeutic potential, for example,
treatment of cancer, heart conditions,
neurological conditions, pain, asthma,
inflammation and other immune
implications. This invention pertains to
highly potent A3 adenosine receptor
agonists, pharmaceutical compositions
comprising such nucleosides, and a
method of use of these nucleosides.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless,
VerDate Aug<31>2005
17:10 Jul 07, 2006
Jkt 208001
38891
within 60 days from the date of this
published Notice, the NIH receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Customs and Border Protection,
Department of Homeland Security,
Washington, DC 20229.
• Facsimile: 202–344–1818.
Instructions: All submissions received
must include the words ‘‘Department of
Homeland Security’’ and the docket
number for this action. Comments
received will be posted without
alteration at https://www.regulations.gov,
including any personal information
provided.
Docket: For access to the docket to
read background documents or
comments received by the CBP
Advisory Committee, go to https://
www.regulations.gov.
Dated: June 29, 2006.
David R. Sadowski,
Acting Director, Division of Technology
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.
[FR Doc. E6–10727 Filed 7–7–06; 8:45 am]
Mr.
Roberto Williams, Cost Management
Division, 1300 Pennsylvania Avenue,
NW., Suite 4.5A, Customs and Border
Protection, Department of Homeland
Security, Washington, DC 20229,
telephone 202–344–1101; facsimile,
202–344–1818; e-mail:
Roberto.M.Williams@dhs.gov.
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Bureau of Customs and Border
Protection
[USCBP–2006–0060]
Airport and Seaport Inspections User
Fee Advisory Committee
Customs and Border Protection,
Department of Homeland Security.
ACTION: Notice of meeting.
AGENCY:
SUMMARY: The Customs and Border
Protection (‘‘CBP’’) Airport and Seaport
Inspections User Fee Advisory
Committee (‘‘Advisory Committee’’) will
meet in open session.
DATES: Tuesday, August 22, 2006, 1 p.m.
to 4 p.m.
ADDRESSES: The meeting will be held at
Conference Room B 1.5–10, Ronald
Reagan Building, 1300 Pennsylvania
Avenue, NW., Washington, DC.
If you desire to submit comments,
they must be submitted by August 8,
2006. Comments must be identified by
USCBP–2006–0060 and may be
submitted by one of the following
methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• E-mail:
Roberto.M.Williams@dhs.gov. Include
docket number in the subject line of the
message.
• Mail: Mr. Roberto Williams, Cost
Management Division, 1300
Pennsylvania Avenue, NW., Suite 4.5A,
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
FOR FURTHER INFORMATION CONTACT:
The fourth
meeting of the CBP Advisory Committee
will be held at the date, time and
location specified above. This notice
also announces the expected agenda for
the meeting (see below).
The Advisory Committee was
established pursuant to section 286(k) of
the Immigration and Nationality Act
(INA), codified at title 8 U.S.C. 1356(k),
which references the Federal Advisory
Committee Act (5 U.S.C. App. 1 et seq.).
With the merger of the Immigration and
Naturalization Service into the
Department of Homeland Security, the
Advisory Committee’s responsibilities
were transferred from the Attorney
General to the Commissioner of CBP
pursuant to section 1512(d) of the
Homeland Security Act of 2002.
The Advisory Committee held its first
meeting under the direction of CBP on
October 22, 2003 (see 68 FR 56301,
September 30, 2003). Among other
things, the committee is tasked with
advising the CBP Commissioner on
issues related to CBP inspection
services. This advice includes, but is not
limited to, the level and the
appropriateness of the following fees
assessed for CBP services: the
immigration user fee pursuant to 8
U.S.C. 1356(d), the customs inspection
user fee pursuant to 19 U.S.C. 58c(a)(5),
and the agriculture inspection user fee
pursuant to 21 U.S.C 136a.
This meeting is open to the public.
Public participation in the deliberations
is welcome; however, please note that
matters outside of the scope of this
committee will not be discussed.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\10JYN1.SGM
10JYN1
]]>Agencies
[Federal Register Volume 71, Number 131 (Monday, July 10, 2006)]
[Notices]
[Pages 38890-38891]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-10727]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: (N)-Methanocarba
Adenosine Derivative as A3 Receptor Agonists
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 38891]]
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services, is contemplating the grant of
an exclusive license worldwide to practice the invention embodied in:
International Patent Application PCT/US2005/031678 filed September 2,
2005 entitled, ``(N)-Methanocarba Adenosine Derivative as A3 Receptor
Agonists'', to Can-Fite BioPharma, Ltd. having a place of business in
Petach-Tikva, Israel. The contemplated exclusive license may be limited
to an FDA approvable human therapeutic for cancer, autoimmune and other
inflammatory diseases. The United States of America is the assignee of
the patent rights in this invention.
DATES: Only written comments and/or application for a license which is
received by the NIH Office of Technology Transfer on or before
September 8, 2006 will be considered.
ADDRESSES: Request for a copy of the patent, inquiries, comments, and
other materials relating to the contemplated license should be directed
to: Norbert Pontzer, Technology Licensing Specialist, Office of
Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: 301-435-
5502; Facsimile: 301-402-0220; e-mail: pontzern@mail.nih.gov.
SUPPLEMENTARY INFORMATION: Researchers have been pursuing compounds
that activate or inhibit adenosine A3 receptors because these cell
membrane proteins have a wide range of physiological and disease-
related effects and are thus considered to be promising drug targets.
The adenosine A3 receptors are G-protein-coupled receptors and are
found mostly in brain, lung, liver, heart, kidney, and testis. When
this receptor is activated moderately, a cytoprotective effect is
observed, such as reducing damage to heart cells from lack of oxygen.
However, at high levels of stimulation they can cause cell death. Both
agonists and antagonists are being tested for therapeutic potential,
for example, treatment of cancer, heart conditions, neurological
conditions, pain, asthma, inflammation and other immune implications.
This invention pertains to highly potent A3 adenosine receptor
agonists, pharmaceutical compositions comprising such nucleosides, and
a method of use of these nucleosides.
The prospective exclusive license will be royalty-bearing and will
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.
The prospective exclusive license may be granted unless, within 60 days
from the date of this published Notice, the NIH receives written
evidence and argument that establishes that the grant of the license
would not be consistent with the requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: June 29, 2006.
David R. Sadowski,
Acting Director, Division of Technology Development and Transfer,
Office of Technology Transfer, National Institutes of Health.
[FR Doc. E6-10727 Filed 7-7-06; 8:45 am]
BILLING CODE 4140-01-P
